P
Patrick S. Parfrey
Researcher at Memorial University of Newfoundland
Publications - 17
Citations - 5628
Patrick S. Parfrey is an academic researcher from Memorial University of Newfoundland. The author has contributed to research in topics: Randomized controlled trial & Kidney disease. The author has an hindex of 5, co-authored 17 publications receiving 5277 citations. Previous affiliations of Patrick S. Parfrey include Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Mark J. Sarnak,Andrew S. Levey,Anton C. Schoolwerth,Josef Coresh,Bruce F. Culleton,L. Lee Hamm,Peter A. McCullough,Bertram L. Kasiske,Ellie Kelepouris,Michael J. Klag,Patrick S. Parfrey,Marc A. Pfeffer,Leopoldo Raij,David J. Spinosa,Peter W.F. Wilson +14 more
TL;DR: There was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population, and the task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events.
Journal ArticleDOI
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Mark J. Sarnak,Andrew S. Levey,Anton C. Schoolwerth,Josef Coresh,Bruce F. Culleton,L. Lee Hamm,Peter A. McCullough,Bertram L. Kasiske,Ellie Kelepouris,Michael J. Klag,Patrick S. Parfrey,Marc A. Pfeffer,Leopoldo Raij,David J. Spinosa,Peter W.F. Wilson +14 more
TL;DR: There was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population, and the task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events.
Journal ArticleDOI
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm
Hicham Skali,Julie Lin,Marc A. Pfeffer,Chao-Yin Chen,Mark E. Cooper,John J.V. McMurray,Allen R. Nissenson,Allen R. Nissenson,Giuseppe Remuzzi,Jerome Rossert,Patrick S. Parfrey,Nairne Scott-Douglas,Ajay K. Singh,Robert D. Toto,Hajime Uno,Peter Ivanovich +15 more
TL;DR: Most patients with moderate anemia, non-dialysis-dependent CKD, and type 2 diabetes are able to maintain a stable Hb level without implementing long-term erythropoiesis-stimulating agent therapy.
Book ChapterDOI
On Framing the Research Question and Choosing the Appropriate Research Design
Patrick S. Parfrey,Pietro Ravani +1 more
TL;DR: The goal of research design is to minimize error, ensure adequate samples, measure input and output variables appropriately, consider external and internal validities, limit bias, and address clinical as well as statistical relevance.
Book ChapterDOI
Modeling longitudinal data, II: standard regression models and extensions.
TL;DR: Extended models are necessary to handle complexities related to clustered data and repeated measurements of time-varying predictors or outcomes in longitudinal studies.